Skip to main content

Table 6 Results of cost-effectiveness analyses, Urinary tract infection model

From: Risk-stratification in febrile infants 29 to 60 days old: a cost-effectiveness analysis

 

Cost ($)

Incremental Cost ($)

Effectiveness (QALY)

Incremental Effectiveness (QALY)

ICER ($/QALY)

PECARN a

$3422

0.842

Step-by-Step

$3505

$83

0.842

−0.0002

Dominatedb

Boston

$3731

$310

0.838

−0.004

Dominated

Rochester

$3995

$573

0.841

−0.001

Dominated

Clinical suspicion

$4521

$1099

0.837

−0.005

Dominated

Philadelphia

$4774

$1352

0.839

−0.003

Dominated

  1. aBold text: Favored strategy at a $100,000 per QALY
  2. bA dominated strategy is more costly and less effective than other strategies
  3. QALY quality adjusted life years, ICER incremental cost-effectiveness ratio, PECARN Pediatric Emergency Care Applied Research Network